On this page
TruNativ bags $30M Series B led by OrbiMed to scale clean-label nutrition play
Our read
TruNativ's $30M Series B is a green light to operationalize omni-channel distribution across D2C, quick commerce, modern trade, and pharmacy simultaneously—test channel-specific SKU and pricing playbooks before scaling spend.
The report,
Mumbai-based clean-label nutrition D2C brand TruNativ raised $30M Series B led by OrbiMed (primary plus secondary). Funds will scale distribution across D2C, quick commerce, modern trade, pharmacy, and expand its B2B2C ingredient business across sugar substitutes, protein, gut health, and wellness.
Reported figures
From the report. Source details below
- founded 2019
- 5 nutrition categories
- OrbiMed AUM ~$20B
Why it matters for the brand
TruNativ's dual D2C + B2B2C ingredient model (sugar substitutes, protein, gut health) makes it a strategic bolt-on target for FMCG majors or pharma players seeking instant clean-label portfolio depth and ingredient supply leverage.